Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381583 · ClinicalTrials.gov registry record
A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 658
- Enrollment target
NCT06381583: Completed study, sponsored by City of Hope Medical Center.
NCT06381583 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 658 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06381583 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 658 participants
- Enrollment target
Study Summary
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.
Primary Outcome
True positive rate: the probability of a positive test result, conditioned on the individual truly being positive
Interventions
- DIAGNOSTIC_TEST EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2024-04-24 |
What the finished NCT06381583 record still lists
NCT06381583 is an observational study that tracks outcomes without assigning an intervention. The registered 658 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) is the first listed.
NCT06381583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06381583 about?
NCT06381583 is a clinical study titled "A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma". This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.
What is the current status of trial NCT06381583?
This trial is currently completed. The enrollment target is 658 participants. The study started on 2023-04-15. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT06381583?
The interventions under investigation include: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06381583?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI